The fibroblast growth factor receptor 4 (FGFR4) Arg388 allele correlates with survival in head and neck squamous cell carcinoma

被引:52
|
作者
Andrade, Valeria Cristina da Costa
Parise, Orlando, Jr.
Hors, Cora Pereira
Martins, Poliana Cristina de Melo
Silva, Alexandre Pacheco
Garicochea, Bernardo
机构
[1] Pontificia Univ Catolica Rio Grande do Sul, Ctr Clin, Hosp Sao Lucas, BR-90630010 Porto Alegre, RS, Brazil
[2] Sirio Libanes Hosp, Sao Paulo, Brazil
[3] Pontificia Univ Catolica Rio Grande Do Sul, Med Sch, Oncol Dept, Porto Alegre, RS, Brazil
[4] Lab Mol Genet, Sao Paulo, Brazil
基金
巴西圣保罗研究基金会;
关键词
FGFR4; head and neck squamous cell carcinoma; prognosis; polymorphism;
D O I
10.1016/j.yexmp.2006.05.003
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Background: The increased expression of the fibroblast growth factor receptor 4 (FGFR4) has been identified in many human cancers. Recently, a single nucleotide polymorphism changing the sense codon 388 from glycine to arginine was identified in the FGFR4 gene. The FGFR4 Arg(388) allele was found to be associated with a poor prognosis for positive node breast cancer, high-grade soft-tissue sarcoma, colon carcinoma, and head and neck squamous cell carcinoma (HNSCC). Methods: We decided to verify the impact of the FGFR4 Arg(388) allele on survival as well as its association with histoclinical data in 75 cases of HNSCC. The FGFR4 Arg(388) allele was detected by PCR-RFLP and DNA sequencing. Results: The FGFR4 Arg(388) allele was detected in 42.5% of the tumors (37% heterozygous Gly/Arg and 5.5% homozygous Arg/Arg). The presence of at least one Arg allele was significantly correlated with reduced overall survival after 24 months of follow-up. The cases involving the Arg allele presented an increased mortality risk of 2.2 if compared to the non-carrier cases. Conclusion: The FGFR4 Arg 388 allele is associated with a shortened survival. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:53 / 57
页数:5
相关论文
共 50 条
  • [21] The Fibroblast Growth Factor Receptor-4 Arg388 Allele Is Associated with Higher Grade and Lymphovascular Space Invasion in Endometrioid Type of Endometrial Adenocarcinoma
    Clarke, B. A.
    Ghazarian, M. D.
    Ezzat, S.
    Asa, S. L.
    LABORATORY INVESTIGATION, 2009, 89 : 210A - 210A
  • [22] The fibroblast growth factor receptor gene Arg388 allele is not associated with early lymph node metastasis of breast cancer
    Becker, N
    Nieters, A
    Chang-Claude, J
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2003, 12 (06) : 582 - 583
  • [23] Expression of acidic fibroblast growth factor (aFGF) and fibroblast growth factor receptor 4 (FGFR4) in breast fibroadenomas
    La Rosa, S
    Sessa, F
    Colombo, L
    Tibiletti, MG
    Furlan, D
    Capella, C
    JOURNAL OF CLINICAL PATHOLOGY, 2001, 54 (01) : 37 - 41
  • [24] Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects
    Lu, Xiaoyun
    Chen, Hao
    Patterson, Adam V.
    Smaill, Jeff B.
    Ding, Ke
    JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (06) : 2905 - 2915
  • [25] FGFR4 Arg388 genotype is associated with pathological complete response to neoadjuvant chemotherapy for primary breast cancer
    Marme, F.
    Werft, W.
    Benner, A.
    Burwinkel, B.
    Sinn, P.
    Sohn, C.
    Lichter, P.
    Hahn, M.
    Schneeweiss, A.
    ANNALS OF ONCOLOGY, 2010, 21 (08) : 1636 - 1642
  • [26] In vitro investigation of significance of fibroblast growth factor receptor type 4 (FGFR4) in RCC cell lines
    Narisawa, Takafumi
    Sakurai, Toshihiko
    Naito, Sei
    Ito, Hiromi
    Kanno, Hidenori
    Ichiyanagi, Osamu
    Kato, Tomoyuki
    Tsuchiya, Norihiko
    CANCER SCIENCE, 2018, 109 : 329 - 329
  • [27] Fibroblast growth factor receptor 4 (FGFR4) and fibroblast growth factor 19 (FGF19) autocrine enhance breast cancer cells survival
    Tiong, Kai Hung
    Tan, Boon Shing
    Choo, Heng Lungh
    Chung, Felicia Fei-Lei
    Hii, Ling-Wei
    Tan, Si Hoey
    Khor, Nelson Tze Woei
    Wong, Shew Fung
    See, Sze-Jia
    Tan, Yuen-Fen
    Rosli, Rozita
    Cheong, Soon-Keng
    Leong, Chee-Onn
    ONCOTARGET, 2016, 7 (36) : 57633 - 57650
  • [28] Fibroblast growth factor receptor 4 (FGFR4): a targetable regulator of drug resistance in colorectal cancer
    R C Turkington
    D B Longley
    W L Allen
    L Stevenson
    K McLaughlin
    P D Dunne
    J K Blayney
    M Salto-Tellez
    S Van Schaeybroeck
    P G Johnston
    Cell Death & Disease, 2014, 5 : e1046 - e1046
  • [29] Fibroblast Growth Factor Receptor 4 (FGFR4) in Cushing Disease Outcome: Influence of Expression and of the G388R Functional Polymorphism.
    Brito, L. P.
    Lerario, A. M.
    Bronstein, M. D.
    Mendonca, B. B.
    Fragoso, M. C. B. V.
    ENDOCRINE REVIEWS, 2010, 31 (03)
  • [30] Fibroblast growth factor receptor 4 (FGFR4): a targetable regulator of drug resistance in colorectal cancer
    Turkington, R. C.
    Longley, D. B.
    Allen, W. L.
    Stevenson, L.
    McLaughlin, K.
    Dunne, P. D.
    Blayney, J. K.
    Salto-Tellez, M.
    Van Schaeybroeck, S.
    Johnston, P. G.
    CELL DEATH & DISEASE, 2014, 5 : e1046 - e1046